UK PARLIAMENT…
Pandemic Response and Recovery APPG Co-Chair Esther McVey (MP) said:
“What we heard has been extremely concerning.”
“The entire system is failing patients, from start to finish.”
“The regulator, the MHRA’s approach to patient safety, the inadequacy of the Yellow Card system for reporting suspected adverse drug reactions… are all compromised and that is severely compromising patient safety.”
web page:
=========
appgpandemic.org/news/yellow-card
“Systems across other countries such as Denmark, Norway and Sweden are better at identifying adverse reactions, as we saw with VITT caused by the AstraZeneca vaccine”
“Should the MHRA, our regulatory body, be primarily funded by fees derived from services to the pharmaceutical industry? ”
“The bottom line is that the MHRA has failed in its remit to keep patients safe.”
“Its approach to patient safety requires a radical overhaul encompassing legislative changes on reporting and, in a system beset by conflicts of interest, changes to how the MHRA is funded.”
“A failure to act will only lead to more harm.”
“Enough independent reports have criticised the MHRA, most recently IMMDS Review, chaired by Baroness Cumberlege. It is now time for a root and branch overhaul of the MHRA, to separate their regulatory approval duties from their post marketing pharmacovigilance and improvements to the Yellow Card reporting system.
“Unfortunately we have heard the disturbing information that adverse reactions are not being properly recorded.”
“We have also heard significant concerns raised about the MHRA and their ability to properly monitor drug safety and detect any potential safety signals.”
Full minutes link to .pdf:
==========================
appgpandemic.org/docs/17072023.pdf
h/t S-man